For the second time in a year and a half, clinical trials of the Opdivo drug failed to impress and the stock collapsed. On Mon Apr 16 2018 the loss was 8%. In August 2016 it was 16%.
These types of stock declines can damage a portfolio and rarely are there any warning signs.
That though does not mean investors are at the mercy of the market. This short article looks at how an investor can protect their trade against market gyrations and stock collapses through a very simple method.
This Bristol-Myers Squibb Stock article is for FullyInformed Members.
Bristol-Myers Squibb Stock – Apr 16 2018